Latest News

Stay up to date with the latest developments in myasthenia gravis research, advocacy, and community support. Explore news, events, and policy updates to stay informed and get involved.

Browse our categories to explore stories relevant to you, and stay connected with the MG community.

All
  • All
  • About MAA News Items
  • Annual Conference News Items
  • Art With Heart News Items
  • Clinical Trials
  • Get Involved News Items
  • Health Professionals News Items
  • Living with MG News Items
  • MG Awareness Month News Items
  • Patient Tool Kit
  • Policy Makers News Items
  • Understanding MG News Items
  • Webinar
PatientReportedSurveyMAAImage
Patient reported outcome survey closing soon
23 January 2022

The Patient Reported Side-Effects Experience Survey is closing soon.

MAA Covid-19 Vaccination Announcement
4 January 2022

An update to COVID-19 Vaccination

UPDATED – Patient Reported Outcome Survey Progress
13 December 2021

Take part in Patient Reported Outcome Survey.

MAA 2020-2021 ANNUAL REPORT
5 December 2021

The Myasthenia Alliance Australian 2020-2021 Annual Report is available.

Patient Reported Outcome Survey Progress
23 November 2021

Take part in Patient Reported Outcome Survey.

Prof. Steve Vucic talks about the Patient Reported Survey Project.
28 October 2021

An interesting and informative podcast has been produced to discuss the latest myasthenia research project.

RITUXIMAB PBS LISTED!
20 October 2021

Rituximab has now been listed on the Pharmaceutical Benefits Scheme.

Recommendations on the use of a 3rd Primary Dose of COVID-19 Vaccinations for People Severely Immunocompromised
12 October 2021

Recommendations on the use of a 3rd Primary Dose of COVID-19 Vaccinations for People Severely Immunocompromised

MG PATIENT REPORTED OUTCOME SURVEY
8 October 2021

The “Myasthenia Gravis Patient Reported Outcome Survey” Research Project is now ready for patient input!

MESTINON SHORTAGE
14 July 2021

The supply of the 60 mg dose of Mestinon is expected to be disrupted until late August.